Status:

COMPLETED

The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO

Lead Sponsor:

Australian and New Zealand Intensive Care Research Centre

Collaborating Sponsors:

The Alfred

Conditions:

Mechanical Ventilation Complication

Severe Acute Respiratory Infection

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Patients who are critically ill in intensive care with moderate to severe acute respiratory infection often require mechanical ventilation. Prolonged ventilation increases the risk of lung damage and ...

Detailed Description

Prolonged mechanical ventilation is standard care for SARI and is associated with long term functional complications: Current guidelines recommend that mechanical ventilation, including protective lun...

Eligibility Criteria

Inclusion

  • Laboratory confirmed severe acute respiratory infection (SARI) pneumonitis such as Coronavirus disease of 2019 (COVID-19) or influenza, AND
  • ≥5 days of mechanical ventilation, AND
  • Moderate to severe respiratory failure as shown by either the ratio of partial pressure of oxygen and the fracture of inspired oxygen (PaO2:FiO2 Rati)o \<150 for \>6 hours OR the potential of hydrogen (pH) \<7.30 with carbon dioxide (CO2) \>50mmHg for 6 hours, AND
  • Are unable to pass a spontaneous breathing trial.

Exclusion

  • Age ≥70 year old
  • Extubation likely in next 24-48 hours
  • Duration of mechanical ventilation ≥7days
  • ≥2 non-pulmonary organ failures (as scored by the sequential oxygen failure assessment (SOFA) score)
  • Need for immediate VV ECMO (as per EOLIA (research study) criteria\*)
  • Requirement for VA ECMO
  • Clinical frailty or ≥2 major comorbidities
  • The physician deems the study is not in the patient's interest
  • EOLIA criteria (P:F \<50 for 3 hours, P:F\<80 for 6 hours, pH\<7.25 with carbon dioxide partial pressure (PCO2) \>60 for \>6 hours

Key Trial Info

Start Date :

March 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT04708457

Start Date

March 1 2021

End Date

December 31 2022

Last Update

October 4 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

The Alfred Hospital

Melbourne, Victoria, Australia, 3004

2

Charite Universitatmedizin

Berlin, Germany, 10117

The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO | DecenTrialz